DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.47

Change

-0.04 (-0.47)%

Market Cap

USD 0.17B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.34 (+0.33%)

USD 17.87B
IVV:AU iShares Core S&P 500 AUD

+0.26 (+0.41%)

USD 11.60B
VGS:AU Vanguard MSCI International Sh..

+0.79 (+0.56%)

USD 10.39B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.22 (+0.37%)

USD 7.35B
IOZ:AU Ishares Core S&P/Asx 200

+0.10 (+0.30%)

USD 6.40B
STW:AU SPDR® S&P/ASX 200 Fund

+0.20 (+0.27%)

USD 5.57B
VTS:AU Vanguard US Total Market Share..

+2.25 (+0.48%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

+0.16 (+0.32%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

-0.14 (-0.33%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.45 (+0.33%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.76% 93% A 73% C
Dividend Return 0.35% 11% F 8% B-
Total Return 8.11% 93% A 74% C
Trailing 12 Months  
Capital Gain -0.70% 11% F 50% F
Dividend Return 2.93% 41% F 33% F
Total Return 2.23% 12% F 49% F
Trailing 5 Years  
Capital Gain 39.77% 71% C- 72% C
Dividend Return 12.08% 28% F 27% F
Total Return 51.84% 65% D 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.78% 64% D 55% F
Dividend Return 8.53% 63% D 53% F
Total Return 1.75% 57% F 37% F
Risk Return Profile  
Volatility (Standard Deviation) 8.50% 65% D 92% A
Risk Adjusted Return 100.32% 89% A- 96% N/A
Market Capitalization 0.17B 33% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.